Collectively, these findings highlight the potential of targeting DNA damage pathways, such as via restoring expression of repair factors like KAT5, ATR, FANCD2 and ERCC1 in kidney cells, as a therapeutic approach to slow down the progression of kidney disease in both tubular cells and podocytes. Here, ERCC1 is linked to kidney disorder.